CollabRx, Inc. (NASDAQ: CLRX) and The Jackson Laboratory said they have announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX.
The partnership with JAX represents CollabRx´s first such relationship with a large and influential non-profit biomedical research institute and demonstrates the company´s accelerating pace of business and channel development in 2014.
Under the terms of the agreement, CollabRx medical and scientific knowledge will be incorporated into the results of genetic sequencing-based tests in oncology provided by JAX. JAX will leverage CollabRx´s dynamically updated knowledge base in molecular medicine, ensuring that the latest medical and scientific data is made available to ordering physicians to aid in their interpretation of test results and inform patient-treatment planning. CollabRx´s knowledge base includes the clinical impact of specific genetic profiles and is supported by its large and growing network of over 75 leading clinical practitioners in the United States and Europe.
CollabRx, Inc. is a recognized leader in cloud-based expert systems to inform healthcare decision-making. More information may be obtained at http://www.collabrx.com.
The Jackson Laboratory is an independent, nonprofit biomedical research institution and National Cancer Institute-designated Cancer Center based in Bar Harbor, Maine, with a facility in Sacramento, Calif., and a new genomic medicine institute in Farmington, Conn. Its website is at http://www.jax.org/.